Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer-Reference-Cited by-同舟云学术

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer

Published:2023-03 Issue: Volume:170 Page:221-228
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Davidson T.M.,Lebreton C.L.,Hendricksen A.E. Wahner,Atkinson H.J.,Larson M.C.,Oberg A.L.,Provencher D.M.,Glaspy J.A.,Karlan B.Y.,Slamon D.J.,Konecny G.E.,Ray-Coquard I.L.

Funder

Mayo Clinic

Amgen

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference44 articles.

1. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis;Bristow;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2002

2. Arbeitsgemeinschaft Gynäkologische Onkologie ovarian Cancer study group, a randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer;du Bois;J. Natl. Cancer Inst.,2003

3. Incorporation of bevacizumab in the primary treatment of ovarian Cancer;Burger;N. Engl. J. Med.,2011

4. A Phase 3 trial of bevacizumab in ovarian Cancer;Perren;N. Engl. J. Med.,2011

5. Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer;Moore;N. Engl. J. Med.,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extracellular Interactors of the IGF System: Impact on Cancer Hallmarks and Therapeutic Approaches;International Journal of Molecular Sciences;2024-05-29

2. Top advances of the year: Ovarian cancer;Cancer;2023-12-15